From Barchart:

The DEA is re-evaluating the federal classification of marijuana, impacting the cannabis industry. Investors are keeping a close eye on three cannabis stocks priced under $5, looking for potential opportunities for growth. This development has the potential to significantly impact the industry, making it a key concern for investors. As the review continues, investors are advised to closely monitor the progress and potential changes in federal classification. The outcome of the review could have a significant impact on the future of these cannabis stocks, making it a crucial development to follow in the industry.



Read more: 3 Cannabis Stocks Under $5 to Consider as the DEA Reviews Drug Status